• Home
  • Neuroendocrine Tumors

Neuroendocrine Tumors

Image placeholder title
Neuroendocrine Tumors

The CancerConnect Neuroendocrine Tumors Newsletter

Image placeholder title
Neuroendocrine Tumors

Lutathera Pepetide Receptor Radionuclide Therapy for NETs

Image placeholder title
Neuroendocrine Tumors

FDA Approves Lutathera for Treatment for Certain Digestive Tract Cancers

Image placeholder title
Neuroendocrine Tumors

Azedra® - Frequently Asked Questions About Azedra® (iobenguane I 131)

Image placeholder title
Neuroendocrine Tumors

FDA Designates Therapy for Azedra in Pheochromocytoma and Paraganglioma

Image placeholder title
Neuroendocrine Tumors

FDA Approves Iobenguane I 131 (Azedra) for Rare Neuroendocrine Tumors

Image placeholder title
Neuroendocrine Tumors

Xermelo-new option for controlling symptoms of Carcinoid Syndrome

Image placeholder title
Neuroendocrine Tumors

Afinitor Promising in Neuroendocrine Tumors Originating in GastrointestinalTract

Image placeholder title
Neuroendocrine Tumors

Sutent Delays Progression of Pancreatic Neuroendocrine Tumors

Image placeholder title
Neuroendocrine Tumors

Sutent Approved for Pancreatic Neuroendocrine Tumors (PNET)

Image placeholder title
Neuroendocrine Tumors

Afinitor and Temodar Active against Pancreatic Neuroendocrine Tumors

Image placeholder title
Neuroendocrine Tumors

Afinitor Approved for Pancreatic Neuroendocrine Tumors

Image placeholder title
Neuroendocrine Tumors

Afinitor Delays Progression of Advanced Pancreatic Neuroendocrine Tumors

Image placeholder title
Neuroendocrine Tumors

CancerConnect Launches On line Community for Patients with Neuroendocrine Tumors

Image placeholder title
Neuroendocrine Tumors

Delcath Receives Orphan Drug Designation for Treatment of Neuroendocrine Tumors